Abstract :

Hepatocellular carcinoma (HCC) has become the second most common cause of cancer-related death worldwide, with approximately 782,500 new cases and 745,500 deaths occurring in the global during 2012. The main objective of the study is to find the therapeutic role of miRNAs in Hepatocellular Carcinoma (HCC). This study was conducted using a systematic search on Google scholar, Pubmed and Web of science published until 20^th June 2020. The cited references of retrieved articles and previous reviews were also manually checked to identify any additional eligible studies. MiRNAs perform their tumor suppressor functions through downregulating oncogene expression. Increasing evidence suggests that miRNAs are essential for the regulation of liver development, regeneration, and metabolic functions. It is concluded that deregulation of miRNAs significantly contributes to the development of HCC. miRNAs mainly functions to down regulate the expression of targeted genes. However, they may have other yet unknown functions including the activation of gene transcription.

 

---

Keywords :

Carcinoma, Cellular, Liver., MiRNA.

---

References :

1. Goodgame B, Shaheen NJ, Galanko J, El Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov;98(11):2535–42
2. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693.
3. Durazo F.A., Blatt L.M., Corey W.G., Lin J.-H., Han S., Saab S., Busuttil R.W., Tong M.J. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.  Gastroenterol. Hepatol. 2008;23:1541–1548. doi: 10.1111/j.1440-1746.2008.05395.x
4. Sung YK, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003;94:259–262.
5. hu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR. et al. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1) BMC Cancer. 2016;16:806.
6. Koenig AB, Barajas JM, Guerrero MJ, Ghoshal K. A Comprehensive Analysis of Argonaute-CLIP Data Identifies Novel, Conserved and Species-Specific Targets of miR-21 in Human Liver and Hepatocellular Carcinoma. Int J Mol Sci. 2018;19:851
7. Wang C, Wang X, Su Z, Fei H, Liu X, Pan Q. miR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI1. 2015;6:36231–44.
8. Feng X, Jiang J, Shi S, Xie H, Zhou L, Zheng S. Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. Int J Oncol. 2016;49:2600–10.
9. Yang H, Li Y, Zhong X, Luo P, Luo P, Sun R. et al. Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2018;15:4097–104.
10. Yang W, Dou C, Wang Y, Jia Y, Li C, Zheng X. et al. MicroRNA-92a contributes to tumor growth of human hepatocellular carcinoma by targeting FBXW7. Oncol Rep. 2015;34:2576–84.
11. Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T. et al. Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol. 2018 [Epub ahead of print].
12. Zhang JJ, Wang CY, Hua L, Yao KH, Chen JT, Hu JH. miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2. Int J Clin Exp Pathol. 2015;8:5168–74.
13. Wang Y, Chen F, Zhao M, Yang Z, Zhang S, Ye LH. et al. MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3′ UTR. Biochem Biophys Res Commun. 
14. Su SG, Yang M, Zhang MF, Peng QZ, Li MY, Liu LP. et al. miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma. Int J Biochem Cell Biol. 2017;91:53–9.
15. Zeng YB, Liang XH, Zhang GX, Jiang N, Zhang T, Huang JY. et al. miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell Int. 2016;16:63.
16. Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X. et al. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017;108:620–31.
17. Yang J, He Y, Zhai N, Ding S, Li JP, Peng Z. MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma. Front Biosci (Landmark Ed) 2018;23:388–96.
18. Qin J, Luo M, Qian H, Chen W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. 2014;538:342–7.
19. Dai W, Wang C, Wang F, Wang Y, Shen M, Chen K. et al. Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem Biophys Res Commun. 2014;446:541–8.
20. Tang S, Tan G, Jiang X, et al. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.Oncotarget 2016;7:73257-69. 10.18632/oncotarget.12304
21. Zhang K, Chen J, Zhou H, et al. 1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.Cell Death Dis 2018;9:312. 10.1038/s41419-018-0344-0
22. Lu AQ, Lv B, Qiu F, et al. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.Oncol Rep 2017;37:2071-8. 10.3892/or.2017.5498
23. Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma.Hepat Oncol 2016;3:57-9. 10.2217/hep.15.41
24. Wen DY, Huang JC, Wang JY, et al. Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: A comprehensive study using microarray and RNA sequencing data.Oncol Lett 2018;16:6918-29
25. Xu Y, Xia F, Ma L, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.Cancer Lett 2011;310:160-9.